Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

135

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

July 31, 2010

Study Completion Date

December 31, 2010

Conditions
Stomach NeoplasmsEsophageal Neoplasms
Interventions
DRUG

PEP02

"120 mg/m2, IV infusion for 90 minutes on day 1 of each 21 day as a treatment cycle.~Number of Cycles: until progression or unacceptable toxicity develops."

DRUG

irinotecan

300 mg/m2, IV infusion on day 1 of each 21 day as a treatment cycle. Number of Cycles: until progression or unacceptable toxicity develops.

DRUG

docetaxel

"75 mg/m2, IV infusion for 60 minutes on day 1 of each 21 day as a treatment cycle.~Number of Cycles: until progression or unacceptable toxicity develops."

Trial Locations (22)

112

Taipei Veterans General Hospital, Taipei

704

National Cheng Kung University Hospital, Tainan City

25115

Mackay Memorial Hospital, Taipei

28040

Hospital Clínico San Carlos, Madrid

39008

Hospital Universitario Marques de Valdecilla, Santander

36 000

Clinical Hospital Mostar, Mostar

71 000

Clinical Centre University of Sarajevo, Sarajevo

51 000

University Hospital Centre Rijeka, Rijeka

10 000

University Hospital Centre Dubrava, Zagreb

University Hospital Centre Zagreb, Zagreb

135-710

Samsung Medical Center, Seoul

138-736

Asan Medical Center, Seoul

410-769

National Cancer Center, Seoul

08035

Hospital Universitario Vall d'Hebron, Barcelona

03203

Hospital General Universitario de Elche, Elche

Unknown

Chang Gung Memorial Hospital - Chiayi, Chiayi City

Chang Gung Memorial Hospital - LinKou, Linkou District

CB2 2QQ

Addenbrookes Hospital Oncology Center, Cambridge

SE19RT

Guy's & St Thomas' NHS Foundation Trust, London

ME16 9QQ

Kent Oncology Centre, Maidstone Hospital, Maidstone

SO16 6YD

Southampton University Hospital, Southampton

SM2 5PT

The Royal Marsden Hospital, Surrey

Sponsors

Lead Sponsor

All Listed Sponsors
lead

PharmaEngine

INDUSTRY

NCT00813072 - Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma | Biotech Hunter | Biotech Hunter